BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15478165)

  • 1. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection.
    Parke FA; Reveille JD
    Arthritis Rheum; 2004 Oct; 51(5):800-4. PubMed ID: 15478165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection.
    Ferri C; Ferraccioli G; Ferrari D; Galeazzi M; Lapadula G; Montecucco C; Triolo G; Valentini G; Valesini G;
    J Rheumatol; 2008 Oct; 35(10):1944-9. PubMed ID: 18688917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis.
    Roux CH; Brocq O; Breuil V; Albert C; Euller-Ziegler L
    Rheumatology (Oxford); 2006 Oct; 45(10):1294-7. PubMed ID: 16603583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis.
    Cansu DU; Kalifoglu T; Korkmaz C
    J Rheumatol; 2008 Mar; 35(3):421-4. PubMed ID: 18203328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy.
    Chung SJ; Kim JK; Park MC; Park YB; Lee SK
    J Rheumatol; 2009 Nov; 36(11):2416-20. PubMed ID: 19797507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment with etanercept in six patients with chronic hepatitis C infection and systemic autoimmune diseases.
    Cavazzana I; Ceribelli A; Cattaneo R; Franceschini F
    Autoimmun Rev; 2008 Dec; 8(2):104-6. PubMed ID: 19014870
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis.
    Puéchal X; Miceli-Richard C; Mejjad O; Lafforgue P; Marcelli C; Solau-Gervais E; Steinfeld S; Villoutreix C; Trèves R; Mariette X; Guillevin L;
    Ann Rheum Dis; 2008 Jun; 67(6):880-4. PubMed ID: 18037625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.
    Carroll MB; Bond MI
    Semin Arthritis Rheum; 2008 Dec; 38(3):208-17. PubMed ID: 18221983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
    Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis.
    Kuroda T; Wada Y; Kobayashi D; Murakami S; Sakai T; Hirose S; Tanabe N; Saeki T; Nakano M; Narita I
    J Rheumatol; 2009 Nov; 36(11):2409-15. PubMed ID: 19797512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities.
    Vauloup C; Krzysiek R; Greangeot-Keros L; Wendling D; Goupille P; Brault R; Brousse C; Mariette X; Emilie D
    Eur Cytokine Netw; 2006 Dec; 17(4):290-3. PubMed ID: 17353164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study.
    Heiberg MS; Nordvåg BY; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2005 Aug; 52(8):2506-12. PubMed ID: 16052584
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus.
    Marotte H; Fontanges E; Bailly F; Zoulim F; Trepo C; Miossec P
    Rheumatology (Oxford); 2007 Jan; 46(1):97-9. PubMed ID: 16720634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS; Choi CB; Woo JH; Bae KW; Joung CL; Uhm WS; Kim TH; Jun JB; Yoo DH; Lee JT; Bae SC
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report.
    Catrina AI; Trollmo C; af Klint E; Engstrom M; Lampa J; Hermansson Y; Klareskog L; Ulfgren AK
    Arthritis Rheum; 2005 Jan; 52(1):61-72. PubMed ID: 15641091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of tumor necrosis factor inhibitors in patients with RA.
    Trethewey P
    JAAPA; 2002 Sep; 15(9):23-4, 27, 30 passim. PubMed ID: 12395668
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E; Wipff J; Avouac J; Kahan A; Allanore Y
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.